FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367174989> ?p ?o ?g. }

• W4367174989 endingPage "1467" @default.
• W4367174989 startingPage "1459" @default.
• W4367174989 abstract "Endocrine therapy (ET) and ET-based regimens are the preferred first-line treatment options for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HR+/HER2- MBC), while chemotherapy (CT) is commonly used in clinical practice. The aim of this study was to investigate the efficacy and clinical outcome of ET and CT as first-line treatment in Chinese patients with HR+/HER2- MBC.Patients diagnosed with HR+/HER2-MBC between January 1st, 1996 and September 30th, 2018 were screened from the Chinese Society of Clinical Oncology Breast Cancer database. The initial and maintenance first-line treatment, progression-free survival (PFS), and overall survival (OS) were analyzed.Among the 1877 included patients, 1215 (64.7%) received CT and 662 (35.3%) received ET as initial first-line treatment. There were no statistically significant differences in PFS and OS between patients receiving ET and CT as initial first-line treatment in the total population (PFS: 12.0 vs. 11.0 months, P = 0.22; OS: 54.0 vs . 49.0 months, P =0.09) and propensity score matched population. For patients without disease progression after at least 3 months of initial therapy, maintenance ET following initial CT (CT-ET cohort, n = 449) and continuous schedule of ET (ET cohort, n = 527) had longer PFS than continuous schedule of CT (CT cohort, n = 406) in the total population (CT-ET cohort vs. CT cohort: 17.0 vs . 8.5 months; P <0.01; ET cohort vs . CT cohort: 14.0 vs . 8.5 months; P <0.01) and propensity score matched population. OS in the three cohorts yielded the same results as PFS.ET was associated with similar clinical outcome to CT as initial first-line treatment. For patients without disease progression after initial CT, switching to maintenance ET showed superiority in clinical outcome over continuous schedule of CT." @default.
• W4367174989 created "2023-04-28" @default.
• W4367174989 creator A5004829445 @default.
• W4367174989 creator A5022426865 @default.
• W4367174989 creator A5023364371 @default.
• W4367174989 creator A5036680742 @default.
• W4367174989 creator A5052524986 @default.
• W4367174989 creator A5056443419 @default.
• W4367174989 creator A5057748562 @default.
• W4367174989 creator A5076149259 @default.
• W4367174989 creator A5080028212 @default.
• W4367174989 creator A5085142676 @default.
• W4367174989 date "2023-04-27" @default.
• W4367174989 modified "2023-09-30" @default.
• W4367174989 title "Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer" @default.
• W4367174989 cites W1464936406 @default.
• W4367174989 cites W1968993577 @default.
• W4367174989 cites W2046095679 @default.
• W4367174989 cites W2116144791 @default.
• W4367174989 cites W2141414987 @default.
• W4367174989 cites W2204530481 @default.
• W4367174989 cites W2280392213 @default.
• W4367174989 cites W2343589315 @default.
• W4367174989 cites W2399269845 @default.
• W4367174989 cites W2404884142 @default.
• W4367174989 cites W2556970382 @default.
• W4367174989 cites W2558360748 @default.
• W4367174989 cites W2796824128 @default.
• W4367174989 cites W2896846857 @default.
• W4367174989 cites W2940712523 @default.
• W4367174989 cites W2972049666 @default.
• W4367174989 cites W2982150569 @default.
• W4367174989 cites W3014145691 @default.
• W4367174989 cites W3016689694 @default.
• W4367174989 cites W3032690516 @default.
• W4367174989 cites W3081150548 @default.
• W4367174989 cites W3093770108 @default.
• W4367174989 cites W3109378361 @default.
• W4367174989 cites W3115380088 @default.
• W4367174989 cites W3165252948 @default.
• W4367174989 cites W4206666777 @default.
• W4367174989 cites W4220833610 @default.
• W4367174989 doi "https://doi.org/10.1097/cm9.0000000000002676" @default.
• W4367174989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37101355" @default.
• W4367174989 hasPublicationYear "2023" @default.
• W4367174989 type Work @default.
• W4367174989 citedByCount "0" @default.
• W4367174989 crossrefType "journal-article" @default.
• W4367174989 hasAuthorship W4367174989A5004829445 @default.
• W4367174989 hasAuthorship W4367174989A5022426865 @default.
• W4367174989 hasAuthorship W4367174989A5023364371 @default.
• W4367174989 hasAuthorship W4367174989A5036680742 @default.
• W4367174989 hasAuthorship W4367174989A5052524986 @default.
• W4367174989 hasAuthorship W4367174989A5056443419 @default.
• W4367174989 hasAuthorship W4367174989A5057748562 @default.
• W4367174989 hasAuthorship W4367174989A5076149259 @default.
• W4367174989 hasAuthorship W4367174989A5080028212 @default.
• W4367174989 hasAuthorship W4367174989A5085142676 @default.
• W4367174989 hasBestOaLocation W43671749891 @default.
• W4367174989 hasConcept C121608353 @default.
• W4367174989 hasConcept C126322002 @default.
• W4367174989 hasConcept C143998085 @default.
• W4367174989 hasConcept C2775930923 @default.
• W4367174989 hasConcept C2776694085 @default.
• W4367174989 hasConcept C2780739268 @default.
• W4367174989 hasConcept C2908647359 @default.
• W4367174989 hasConcept C530470458 @default.
• W4367174989 hasConcept C71924100 @default.
• W4367174989 hasConcept C72563966 @default.
• W4367174989 hasConcept C99454951 @default.
• W4367174989 hasConceptScore W4367174989C121608353 @default.
• W4367174989 hasConceptScore W4367174989C126322002 @default.
• W4367174989 hasConceptScore W4367174989C143998085 @default.
• W4367174989 hasConceptScore W4367174989C2775930923 @default.
• W4367174989 hasConceptScore W4367174989C2776694085 @default.
• W4367174989 hasConceptScore W4367174989C2780739268 @default.
• W4367174989 hasConceptScore W4367174989C2908647359 @default.
• W4367174989 hasConceptScore W4367174989C530470458 @default.
• W4367174989 hasConceptScore W4367174989C71924100 @default.
• W4367174989 hasConceptScore W4367174989C72563966 @default.
• W4367174989 hasConceptScore W4367174989C99454951 @default.
• W4367174989 hasIssue "12" @default.
• W4367174989 hasLocation W43671749891 @default.
• W4367174989 hasLocation W43671749892 @default.
• W4367174989 hasLocation W43671749893 @default.
• W4367174989 hasLocation W43671749894 @default.
• W4367174989 hasOpenAccess W4367174989 @default.
• W4367174989 hasPrimaryLocation W43671749891 @default.
• W4367174989 hasRelatedWork W2139647583 @default.
• W4367174989 hasRelatedWork W2348231456 @default.
• W4367174989 hasRelatedWork W2354050160 @default.
• W4367174989 hasRelatedWork W2367105124 @default.
• W4367174989 hasRelatedWork W2368979736 @default.
• W4367174989 hasRelatedWork W2369039771 @default.
• W4367174989 hasRelatedWork W2379151083 @default.
• W4367174989 hasRelatedWork W2388730008 @default.
• W4367174989 hasRelatedWork W2791179561 @default.
• W4367174989 hasRelatedWork W3181412252 @default.

• next